Affirmed Therapeutics BV (AFMD) Short Interest Update
Affirmed Therapeutics BV (NASDAQ:AFMD) was the target of a large increase in short interest in the month of September. As of September 15th, there was short interest totalling 996,488 shares, an increase of 31.2% from the August 31st total of 759,494 shares. Approximately 5.4% of the shares of the stock are short sold. Based on an average trading volume of 80,338 shares, the short-interest ratio is presently 12.4 days.
Affirmed Therapeutics BV (NASDAQ:AFMD) opened at 2.73 on Friday. The firm’s 50 day moving average price is $2.78 and its 200-day moving average price is $3.28. The stock’s market cap is $91.42 million. Affirmed Therapeutics BV has a 52 week low of $2.34 and a 52 week high of $8.42.
Affirmed Therapeutics BV (NASDAQ:AFMD) last posted its quarterly earnings results on Wednesday, August 10th. The biopharmaceutical company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.22) by $0.05. Affirmed Therapeutics BV had a negative net margin of 440.97% and a negative return on equity of 49.84%. The company had revenue of $2.07 million for the quarter, compared to analysts’ expectations of $2.10 million. During the same quarter in the prior year, the firm earned ($0.19) earnings per share. The company’s revenue was down 6.4% on a year-over-year basis. Analysts expect that Affirmed Therapeutics BV will post ($1.12) EPS for the current year.
A number of equities research analysts have commented on AFMD shares. Leerink Swann upgraded Affirmed Therapeutics BV from a “market perform” rating to an “outperform” rating in a report on Monday, July 18th. Jefferies Group reiterated a “hold” rating on shares of Affirmed Therapeutics BV in a report on Tuesday, August 9th. Three equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $8.63.
Several institutional investors have recently bought and sold shares of the stock. Wellington Management Group LLP boosted its position in Affirmed Therapeutics BV by 237.2% in the first quarter. Wellington Management Group LLP now owns 3,561,141 shares of the biopharmaceutical company’s stock valued at $13,318,000 after buying an additional 2,505,031 shares in the last quarter. Perceptive Advisors LLC bought a new position in Affirmed Therapeutics BV during the second quarter valued at approximately $1,821,000. Moore Capital Management LP bought a new position in Affirmed Therapeutics BV during the first quarter valued at approximately $281,000. Paloma Partners Management Co bought a new position in Affirmed Therapeutics BV during the second quarter valued at approximately $142,000. Finally, BlackRock Fund Advisors boosted its position in Affirmed Therapeutics BV by 2.4% in the first quarter. BlackRock Fund Advisors now owns 817,240 shares of the biopharmaceutical company’s stock valued at $3,056,000 after buying an additional 18,900 shares in the last quarter. Institutional investors and hedge funds own 42.86% of the company’s stock.
About Affirmed Therapeutics BV
Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company’s product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body’s own immune system to fight tumor cells.
Receive News & Stock Ratings for Affirmed Therapeutics BV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Affirmed Therapeutics BV and related stocks with our FREE daily email newsletter.